Molecular Genetics & Genomic Medicine (Dec 2021)

Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)

  • Sumaya Islam,
  • Mehmet Tekman,
  • Sarah E. Flanagan,
  • Lisa Guay‐Woodford,
  • Khalid Hussain,
  • Sian Ellard,
  • Robert Kleta,
  • Detlef Bockenhauer,
  • Horia Stanescu,
  • Daniela Iancu

DOI
https://doi.org/10.1002/mgg3.1674
Journal volume & issue
Vol. 9, no. 12
pp. n/a – n/a

Abstract

Read online

Abstract Background Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.‐167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic coding variant in trans. All patients identified so far are of European descent, suggesting a possible founder effect. Methods We generated high density genotyping data from 11 patients from seven unrelated families, and used this information to identify a common haplotype that included the promoter variant. We estimated the age of the promoter mutation with DMLE+ software, using demographic parameters corresponding to the European population. Results All patients shared a 0.312 Mb haplotype which was absent in 503 European controls available in the 1000 Genomes Project. The age of this mutation was estimated as 105–110 generations, indicating its occurrence around 600 BC, a time of intense migration, which might explain the presence of the same mutations in Europeans around the globe. Conclusion The shared unique haplotype among seemingly unrelated patients is consistent with a founder effect in Europeans.

Keywords